Sustained-Release Gemcitabine-Docetaxel NDV-01 clinical trials
How each study uses Sustained-Release Gemcitabine-Docetaxel NDV-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Sustained-Release Gemcitabine-Docetaxel NDV-01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- NDV-01 (sustained-release gemcitabine-docetaxel)
- 3
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Relmada Therapeutics, Inc. (3)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses Sustained-Release Gemcitabine-Docetaxel NDV-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNot yet recruitingPhase 3Relmada Therapeutics, Inc.NCT07464145Written as NDV-01 (sustained-release gemcitabine-docetaxel)
- A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBTWithdrawnPhase 3Relmada Therapeutics, Inc.NCT07313891Written as NDV-01 (sustained-release gemcitabine-docetaxel)
- A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line TherapyWithdrawnPhase 3Relmada Therapeutics, Inc.NCT07342517Written as NDV-01 (sustained-release gemcitabine-docetaxel)